NCT01881503View on ClinicalTrials.gov

Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

NAEnrolling by invitationINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

Anemia

Interventions

BIOLOGICAL

HBOC-201

HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.

Trial Locations (1)

07631

Englewood Hospital and Medical Center, Englewood

Sponsors

Collaborators (1)

HbO2 Therapeutics LLC

All Listed Sponsors

collaborator

HbO2 Therapeutics LLC

INDUSTRY

lead

Englewood Hospital and Medical Center

OTHER

NCT01881503 - Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia | Biotech Hunter | Biotech Hunter